Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data
| Autor: | Alison Wringe, Basia Zaba, Angela Ramadhani, Bonita Kilama, Jim Todd, Fiona Vanobberghen, Donan Mmbando |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Anti-HIV Agents First line Population antiretroviral therapy Program activities HIV Infections Tanzania Young Adult ANTIRETROVIRAL AGENTS Second line Hiv infected Antiretroviral Therapy Highly Active medicine risk factors Humans Treatment Failure education National data Gynecology education.field_of_study Public Health Environmental and Occupational Health CD4 lymphocyte count Middle Aged Viral Load Antiretroviral therapy Infectious Diseases Parasitology Female Original Research Papers |
| Zdroj: | Tropical Medicine & International Health |
| ISSN: | 1365-3156 1360-2276 |
| Popis: | Objectives Rates of first-line treatment failure and switches to second-line therapy are key indicators for national HIV programmes. We assessed immunological treatment failure defined by WHO criteria in the Tanzanian national HIV programme. Methods We included adults initiating first-line therapy in 2004–2011 with a pre-treatment CD4 count, and ≥6-months of follow-up. We assessed subhazard ratios (SHR) for immunological treatment failure, and subsequent switch to second-line therapy, using competing risks methods to account for deaths. Results Of 121 308 adults, 7% experienced immunological treatment failure, and 2% died without observed immunological treatment failure, over a median 1.7 years. The 6-year cumulative probability of immunological treatment failure was 19.0% (95% CI 18.5, 19.7) and of death, 5.1% (4.8, 5.4). Immunological treatment failure predictors included earlier year of treatment initiation (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text